On April 1, 2025 Domain Therapeutics ("Domain" or "the Company"), the GPCR experts harnessing deep receptor biology to develop breakthrough treatments for patients, reported that it will be presenting new preclinical and clinical data on its key oncology programs – DT-7012, and DT-9081, alongside preclinical findings on its PAR2 biased negative allosteric modulator ( NAM ) program – at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) ( AACR (Free AACR Whitepaper) ) Annual Meeting 2025, taking place in Chicago, US from 25-30 April 2025 (Press release, Domain Therapeutics, APR 1, 2025, View Source [SID1234651715]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster presentations will highlight Domain’s progress in leveraging GPCR-targeting therapies to modulate the tumor microenvironment and enhance anti-cancer immune responses.

Details of the poster presentations are as follows:

Poster Title: Comprehensive Characterization of DT-7012, a Differentiated CCR8-Depleting Antibody for the Treatment of Solid Tumors
Session Category: Experimental and Molecular Therapeutics
Session Title: Antireceptors and Other Biological Therapeutic Agents
Date and Time: Sunday 27th April 2025, 14:00 – 17:00 CDT
Location: Poster Section 15
Poster Board Number: 4
Abstract Number: 7080

DT-7012 – A Differentiated CCR8-Depleting Antibody for Solid Tumors

DT-7012 is a highly selective, fully humanized monoclonal antibody targeting CCR8, a receptor predominantly expressed on tumor-resident regulatory T cells ( Tregs ), which suppress anti-tumor immunity.
The study characterizes DT-7012’s binding properties, effector functions, and Treg-depleting activity, supporting its transition into clinical development.

Poster Title: Clinical PK, PD and safety analysis of a phase I clinical trial of DT-9081, an EP4R-antagonist, for RP2D determination in patients with advanced solid tumors
Session Category: Clinical Research
Session Title: Modifiers of the Tumor Microenvironment
Date and Time: Monday 28th April 2025, 14:00 – 17:00 CDT
Location: Poster Section 30
Poster Board Number: 8
Abstract Number: 7450

DT-9081 – Phase I Clinical Data of an EP4R Antagonist for Advanced Solid Tumors

DT-9081 is an oral EP4 receptor ( EP4R ) antagonist designed to inhibit growth by blocking prostaglandin E2 ( PGE2 )-mediated immune suppression. Interim Phase I results demonstrate DT-9081’s favorable safety profile, linear pharmacokinetics, and dose-dependent inhibition of EP4R signaling, with data supporting the recommended Phase II dose ( RP2D ).

Poster Title: PAR2 inhibitors reduce resistance to immunotherapy against cancer
Session Category: Immunology
Session Title: Interplay between Immune System and Radio-, Chemo- and Targeted Therapies 2
Date and Time: Tuesday 29th April, 14:00 – 17:00 CDT
Location: Poster Section 40
Poster Board Number: 9
Abstract Number: 6606

PAR2 – Pivotal driver of resistance to immune checkpoint blockade ( ICB ) and T cell dysfunction in cancer

PAR2 biased NAM represents a transformative breakthrough in immuno-oncology, targeting tumor resistance to ICB. Preclinical findings demonstrate the unique mode of action of PAR2 inhibition. By reshaping the tumor microenvironment, it reduces immunosuppressive macrophages and increases antigen presentation, fostering robust anti-tumor immune responses and thereby improving patient outcomes.

Stephan Schann, Chief Scientific Officer of Domain Therapeutics, said: "These promising preclinical and clinical results for DT-7012 and DT-9081, alongside the preclinical findings on our PAR2 biased NAM demonstrate Domain’s unmatched knowledge in leveraging deep receptor biology to develop differentiated oncology treatments. We look forward to sharing these promising insights with the scientific community as we continue to push the boundaries to ultimately deliver better treatments and transform patients’ lives."

Abstracts are available in an online itinerary planner found here and will be available in an online only supplement to the AACR (Free AACR Whitepaper) journal Cancer Research one month after the conference.

On April 1, 2025 Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) immunotherapies, reported that company management will participate in the 24th Annual Needham Virtual Healthcare Conference (Press release, Cidara Therapeutics, APR 1, 2025, View Source [SID1234651714]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details are as follows:

Event: 24th Annual Needham Virtual Healthcare Conference
Date: Wednesday, April 9, 2025
Time: 11:00 AM ET
Format: Presentation
Webcast: View Source

A replay of the presentation will be available in the Investors section on the Company’s website at www.cidara.com. The replay of the presentation will be available for 90 days.

Cidara will also participate in one-on-one investor meetings during this event. Investors interested in meeting with Cidara at the conference should contact their Needham representative directly.

On April 1, 2025 Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, reported that management will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, at 12:45 p.m. ET (Press release, Bicycle Therapeutics, APR 1, 2025, View Source [SID1234651712]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside chat will be accessible from the Investor section of the company’s website at www.bicycletherapeutics.com. A replay of the webcast will be archived and available following the event.

On April 1, 2025 Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the "Company"), a leader in PCR-based DNA technologies, reported that Applied DNA Clinical Labs (ADCL), its wholly-owned clinical laboratory subsidiary, is repositioning its TR8 PGx pharmacogenomics testing service to offer tailored subpanels for indication-specific use cases in addition to full panel testing (Press release, Applied DNA Sciences, APR 1, 2025, View Source [SID1234651711]). The first subpanel under ADCL’s new go-to-market strategy is for the pre-emptive testing of patients with genetic variants of the DPYD gene that correlate to potentially reduced or absent DPD enzyme activity necessary to metabolize fluoropyrimidines, specifically capecitabine (branded Xeloda) and fluorouracil (5-FU), two chemotherapy drugs that are widely used as part of the standard of care treatment for patients with certain cancers. The decision by ADCL follows a recent safety announcement by the Food and Drug Administration (FDA) in which the agency highlighted that patients with certain DPYD genetic variants are potentially poor or intermediate metabolizers of these two medications due to DPD enzyme deficiencies and risk drug overexposure and the potential to experience severe, and at times fatal, toxicities when taking them. ADCL’s TR8 PGx test, a 120-target pharmacogenomics panel approved by the New York State Department of Health as a laboratory-developed test comprising more than 33 drug metabolism-related genes, can identify individuals with DPYD genotypes that result in potentially reduced or absent DPD enzyme activity.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Capecitabine and 5-FU are used for the treatment of colorectal, esophageal, stomach, pancreatic, breast, and cervical cancers. Approximately 924,000 prescriptions were written for fluorouracil and capecitabine in 2022, according to the most recent drug usage data available.1 Approximately 1 in 1,000 patients carry two copies of a variant in the DPYD gene, resulting in the absence of the DPD enzyme. Between 3 percent and 8 percent of the general population has one copy of a variant associated with lower levels of the DPD enzyme, showing up more frequently in African Americans.2 These genotypes are at higher risk of adverse side effects from fluorouracil and capecitabine.

"The FDA’s safety announcement underscores the value of genetic testing to guide treatment decisions and improve patient outcomes, and highlights the breadth of our TR8 PGx test and its potential to influence clinical decision-making across multiple therapeutic areas. To this end, we plan to introduce additional TR8 PGx subpanels that target indication-specific use cases where genetic testing has a high correlation with drug efficacy and safety, such as in oncology, cardiology, and psychiatry. We believe this revised go-to-market strategy can lower the barrier to adoption of our PGx testing services and provides enhanced utility to institutions, clinicians, and their patients," stated Dr. James A. Hayward, CEO of Applied DNA.

About TR8 PGx – Pharmacogenomic Testing
The TR8 PGx test analyzes 120 genetic targets across more than 33 genes to inform healthcare providers about how a patient may respond to a wide range of drug therapies used to treat a variety of conditions, such as cardiovascular, oncology, psychiatric, and pain management. Equipped with information about a patient’s genome-based response to medications, healthcare providers can make more informed decisions when selecting prescription medications, thereby optimizing healthcare quality and efficacy.

The test is administered via a simple cheek swab. The TR8 PGx testing service offered by ADCL was approved as a laboratory-developed test by the New York State Department of Health (NYSDOH) in June 2024.

On April 1, 2025 Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, reported its participation in the Jones Las Vegas Healthcare and Technology Innovation Conference, to be held on April 8-9, 2025, at The Venetian Resort in Las Vegas, Nevada (Press release, Anixa Biosciences, APR 1, 2025, View Source [SID1234651710]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mike Catelani, President and CFO of Anixa, will deliver a presentation and be available for one-on-one meetings during the conference.

Details of the presentation are as follows:

Event: Jones Healthcare and Technology Innovation Conference
Date: April 9, 2025
Time: 4:30 PM PT
Location: The Venetian Resort
Webcast: View Source

The Jones Healthcare and Technology Innovation Conference will bring together a select group of innovative companies and institutional investors for a two-day event. The conference will be focused on one-on-one (1×1) meetings, fireside chats, panels, presentations, and signature networking events. Organized by Jones, with marketing support from B2i Digital, Inc., the event offers an opportunity for direct dialogue between senior company executives and investors seeking engagement with innovative management teams.

For more information, a list of participating companies and to submit registration requests about the Jones Las Vegas Healthcare and Technology Innovation Conference, visit their B2i Digital Featured Conference page.